FDA Inspection 1180850 — Daito Pharmaceutical Co., Ltd.
The FDA completed an inspection of Daito Pharmaceutical Co., Ltd. on Sep 16, 2022 in Toyama. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Sep 16, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Toyama (Japan)